GILEAD SCIENCES, INC.
boothcheck covers GILEAD SCIENCES, INC. (GILD) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 3, 2026.
The loudest worry about Gilead is patent risk: Biktarvy alone is $3.36 billion a quarter, and one drug carrying the company invites a cliff fear. The data tempers it. At $123.63 (as of June 27, 2026) the price implies roughly flat operating growth, a low bar, and the company is below the middle of its peer multiple range. The valuation is supported by the relative-multiple and growth-DCF lenses, while asset and earnings-power frames call it expensive. Several methods land above the price, and t
Is GILD overvalued? See what's priced in →
2,256 institutional managers reported holding GILD in 13F filings for the quarter ended 2026-03-31. Together they hold about 82% of the company; the top 10 hold 44%. 207 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 23.9M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GILD has cut its share count 1% over the past five years, spending $6.08B on repurchases. It pays a dividend, and has for 11 years running, raised 10 years straight; the current rate is $3.16 a share annually. Cash returned over the past three years: $10.86B in dividends and $3.94B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at GILD over the trailing three years. Absence is a fact about the company, not a signal. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
GILD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +4.0% | -5.0% |
| 2023-11-08 | -4.0% | +8.5% |
| 2024-02-24 | -0.2% | -11.1% |
| 2024-05-09 | -2.5% | +8.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
GILD's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-05-20 (items 1.01, 2.03, 8.01, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-05-04 (items 5.07, 9.01); 2026-04-28 (items 7.01, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.